Patent · US Active

Pyrazolo[1,5-A]pyrimidines as mark inhibitors

US8946237B2 · kind B2 · utility

1Cited by

2References

11Claims

0Family size

Assignee

Merck Sharp & Dohme LLC · US

Inventors

Jongwon Lim · Lexington, US
Brandon M. Taoka · Brookline, US
Sandra Lee · West Hollywood, US
Alan B. Northrup · Reading, US
Michael D. Altman · Cambridge, US
David L. Sloman · Brookline, US
Matthew G. Stanton · Marlton, US
Njamkou Noucti · Cambridge, US

Key dates

Filing date	Jan 11, 2011
Grant date	Feb 3, 2015
Priority date	—
Expiry date	Oct 30, 2031

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P25/28
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

The invention encompasses pyrazolo[1,5-a]pyrimidine derivatives which selectively inhibit microtubule affinity regulating kinase (MARK) and are therefore useful for the treatment or prevention of Alzheimer's disease. Pharmaceutical compositions and methods of use are also included.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.